|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ZNF335 |
Gene summary for ZNF335 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ZNF335 | Gene ID | 63925 |
| Gene name | zinc finger protein 335 | |
| Gene Alias | MCPH10 | |
| Cytomap | 20q13.12 | |
| Gene Type | protein-coding | GO ID | GO:0000902 | UniProtAcc | Q8IW09 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 63925 | ZNF335 | LZE4T | Human | Esophagus | ESCC | 5.94e-08 | 2.84e-01 | 0.0811 |
| 63925 | ZNF335 | LZE7T | Human | Esophagus | ESCC | 8.30e-06 | 3.70e-01 | 0.0667 |
| 63925 | ZNF335 | LZE8T | Human | Esophagus | ESCC | 1.24e-02 | 1.72e-01 | 0.067 |
| 63925 | ZNF335 | LZE20T | Human | Esophagus | ESCC | 4.91e-06 | 2.41e-01 | 0.0662 |
| 63925 | ZNF335 | LZE24T | Human | Esophagus | ESCC | 5.64e-04 | 2.31e-01 | 0.0596 |
| 63925 | ZNF335 | LZE21T | Human | Esophagus | ESCC | 7.07e-03 | 3.26e-01 | 0.0655 |
| 63925 | ZNF335 | P1T-E | Human | Esophagus | ESCC | 2.74e-12 | 6.63e-01 | 0.0875 |
| 63925 | ZNF335 | P2T-E | Human | Esophagus | ESCC | 4.97e-20 | 2.45e-01 | 0.1177 |
| 63925 | ZNF335 | P5T-E | Human | Esophagus | ESCC | 4.65e-10 | 1.30e-01 | 0.1327 |
| 63925 | ZNF335 | P8T-E | Human | Esophagus | ESCC | 8.68e-16 | 2.38e-01 | 0.0889 |
| 63925 | ZNF335 | P9T-E | Human | Esophagus | ESCC | 6.30e-09 | 2.77e-01 | 0.1131 |
| 63925 | ZNF335 | P10T-E | Human | Esophagus | ESCC | 1.11e-27 | 4.32e-01 | 0.116 |
| 63925 | ZNF335 | P11T-E | Human | Esophagus | ESCC | 3.45e-07 | 4.29e-01 | 0.1426 |
| 63925 | ZNF335 | P12T-E | Human | Esophagus | ESCC | 2.80e-17 | 3.12e-01 | 0.1122 |
| 63925 | ZNF335 | P15T-E | Human | Esophagus | ESCC | 1.66e-19 | 3.97e-01 | 0.1149 |
| 63925 | ZNF335 | P16T-E | Human | Esophagus | ESCC | 4.53e-11 | 2.23e-01 | 0.1153 |
| 63925 | ZNF335 | P20T-E | Human | Esophagus | ESCC | 2.72e-27 | 7.48e-01 | 0.1124 |
| 63925 | ZNF335 | P21T-E | Human | Esophagus | ESCC | 4.86e-15 | 3.27e-01 | 0.1617 |
| 63925 | ZNF335 | P22T-E | Human | Esophagus | ESCC | 5.36e-09 | 8.37e-02 | 0.1236 |
| 63925 | ZNF335 | P23T-E | Human | Esophagus | ESCC | 2.27e-10 | 3.08e-01 | 0.108 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:001657015 | Esophagus | ESCC | histone modification | 323/8552 | 463/18723 | 2.61e-26 | 7.88e-24 | 323 |
| GO:001820514 | Esophagus | ESCC | peptidyl-lysine modification | 259/8552 | 376/18723 | 3.90e-20 | 5.26e-18 | 259 |
| GO:000170119 | Esophagus | ESCC | in utero embryonic development | 243/8552 | 367/18723 | 1.00e-15 | 6.86e-14 | 243 |
| GO:00434143 | Esophagus | ESCC | macromolecule methylation | 199/8552 | 316/18723 | 3.44e-10 | 9.57e-09 | 199 |
| GO:003105614 | Esophagus | ESCC | regulation of histone modification | 106/8552 | 152/18723 | 1.52e-09 | 3.55e-08 | 106 |
| GO:00322592 | Esophagus | ESCC | methylation | 222/8552 | 364/18723 | 2.26e-09 | 5.09e-08 | 222 |
| GO:00400295 | Esophagus | ESCC | regulation of gene expression, epigenetic | 74/8552 | 105/18723 | 2.24e-07 | 3.42e-06 | 74 |
| GO:000647914 | Esophagus | ESCC | protein methylation | 115/8552 | 181/18723 | 9.07e-07 | 1.16e-05 | 115 |
| GO:000821314 | Esophagus | ESCC | protein alkylation | 115/8552 | 181/18723 | 9.07e-07 | 1.16e-05 | 115 |
| GO:001072010 | Esophagus | ESCC | positive regulation of cell development | 172/8552 | 298/18723 | 1.74e-05 | 1.55e-04 | 172 |
| GO:00165718 | Esophagus | ESCC | histone methylation | 89/8552 | 141/18723 | 2.17e-05 | 1.87e-04 | 89 |
| GO:005076710 | Esophagus | ESCC | regulation of neurogenesis | 203/8552 | 364/18723 | 6.10e-05 | 4.68e-04 | 203 |
| GO:00507697 | Esophagus | ESCC | positive regulation of neurogenesis | 131/8552 | 225/18723 | 9.71e-05 | 6.90e-04 | 131 |
| GO:003496814 | Esophagus | ESCC | histone lysine methylation | 72/8552 | 115/18723 | 1.85e-04 | 1.18e-03 | 72 |
| GO:003106013 | Esophagus | ESCC | regulation of histone methylation | 46/8552 | 69/18723 | 3.46e-04 | 2.03e-03 | 46 |
| GO:00519606 | Esophagus | ESCC | regulation of nervous system development | 237/8552 | 443/18723 | 5.02e-04 | 2.78e-03 | 237 |
| GO:001802214 | Esophagus | ESCC | peptidyl-lysine methylation | 79/8552 | 131/18723 | 5.17e-04 | 2.86e-03 | 79 |
| GO:00519625 | Esophagus | ESCC | positive regulation of nervous system development | 149/8552 | 272/18723 | 1.50e-03 | 7.06e-03 | 149 |
| GO:00180231 | Esophagus | ESCC | peptidyl-lysine trimethylation | 31/8552 | 50/18723 | 1.48e-02 | 4.79e-02 | 31 |
| GO:00165707 | Oral cavity | OSCC | histone modification | 270/7305 | 463/18723 | 1.59e-17 | 1.50e-15 | 270 |
| Page: 1 2 3 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ZNF335 | MYOFIB | Colorectum | AD | SUMO1,PDE1B,ABHD13, etc. | 7.85e-02 |  |
| ZNF335 | CYC | Skin | Healthy | KCNQ1OT1,EVPL,PLCG2, etc. | 1.06e-01 |  |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ZNF335 | SNV | Missense_Mutation | novel | c.2574N>C | p.Glu858Asp | p.E858D | Q9H4Z2 | protein_coding | deleterious(0.01) | benign(0.225) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
| ZNF335 | SNV | Missense_Mutation | novel | c.3777N>A | p.His1259Gln | p.H1259Q | Q9H4Z2 | protein_coding | tolerated(0.09) | probably_damaging(0.917) | TCGA-A2-A1G1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ZNF335 | SNV | Missense_Mutation | rs555774487 | c.1856N>A | p.Arg619His | p.R619H | Q9H4Z2 | protein_coding | deleterious(0.03) | possibly_damaging(0.813) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ZNF335 | SNV | Missense_Mutation | c.2174N>G | p.Ser725Cys | p.S725C | Q9H4Z2 | protein_coding | deleterious(0) | possibly_damaging(0.818) | TCGA-B6-A0I6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
| ZNF335 | SNV | Missense_Mutation | novel | c.356N>C | p.Val119Ala | p.V119A | Q9H4Z2 | protein_coding | deleterious(0.01) | benign(0.001) | TCGA-E9-A1ND-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | aromasin | SD |
| ZNF335 | SNV | Missense_Mutation | novel | c.985G>A | p.Glu329Lys | p.E329K | Q9H4Z2 | protein_coding | deleterious(0.01) | possibly_damaging(0.681) | TCGA-OL-A5RW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
| ZNF335 | insertion | Frame_Shift_Ins | novel | c.3972_3973insGAGGTGAGGACTTGGGGACAGGCAGGGAGGGGAGC | p.Gln1325GlufsTer60 | p.Q1325Efs*60 | Q9H4Z2 | protein_coding | TCGA-AR-A0TY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | PD | ||
| ZNF335 | SNV | Missense_Mutation | novel | c.1844N>A | p.Ala615Asp | p.A615D | Q9H4Z2 | protein_coding | deleterious(0.02) | benign(0.116) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| ZNF335 | SNV | Missense_Mutation | novel | c.1372N>T | p.Pro458Ser | p.P458S | Q9H4Z2 | protein_coding | tolerated(0.24) | possibly_damaging(0.715) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| ZNF335 | SNV | Missense_Mutation | rs767339054 | c.3964N>A | p.Glu1322Lys | p.E1322K | Q9H4Z2 | protein_coding | deleterious(0) | probably_damaging(0.98) | TCGA-C5-A7UH-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |